ZL0580

ZL0580, a structurally close analog of ZL0590, induces epigenetic suppression of HIV via selectively binding to BD1 domain of BRD4. ZL0580 induces HIV suppression by inhibiting Tat transactivation and transcription elongation as well as by inducing repressive chromatin structure at the HIV promoter[1][2][3].

Product Specifications

CAS Number

[2377151-10-3]

UNSPSC

12352005

Target

Epigenetic Reader Domain; HIV

Type

Reference compound

Related Pathways

Anti-infection; Epigenetics

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/zl0580.html

Purity

99.42

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C(S(N2CCC[C@H]2C(NC3=CC=CC=C3)=O)(=O)=O)C=C1)NC4=CC=C(C(F)(F)F)C=C4

Molecular Formula

C25H23F3N4O4S

Molecular Weight

532.53

References & Citations

[1]Niu Q, et al. Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV. J Clin Invest. 2019 Jul 22;129 (8) :3361-3373.|[2]Vansant G, et al. Block-And-Lock Strategies to Cure HIV Infection. Viruses. 2020 Jan 10;12 (1) . pii: E84.|[3]Brasier AR, et al. Validation of the epigenetic reader bromodomain-containing protein 4 (BRD4) as a therapeutic target for treatment of airway remodeling. Drug Discov Today. 2020 Jan;25 (1) :126-132.